Diabetes and Second Neoplasia Impact on Prognosis in Pre-Fibrotic Primary Myelofibrosis
The 2016 WHO classification recognized pre-fibrotic primary myelofibrosis (pre-PMF) as a distinct entity. Nevertheless, a prognostic model specific for pre-PMF is still lacking. Our aim was to identify the most relevant clinical, histological, and driver mutation information at diagnosis to evaluate...
Main Authors: | Daniele Cattaneo, Claudia Vener, Elena Maria Elli, Cristina Bucelli, Nicole Galli, Fabrizio Cavalca, Giuseppe Auteri, Donatella Vincelli, Bruno Martino, Umberto Gianelli, Francesca Palandri, Alessandra Iurlo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/7/1799 |
Similar Items
-
Overt-stage primary myelofibrosis after COVID-19 infection: a case report
by: P. Darmada, et al.
Published: (2022-09-01) -
Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome
by: Bruno Deltreggia Benites, et al.
Published: (2013-01-01) -
Prognostic Significance of the Myelodysplastic Syndrome-Specific Comorbidity Index (MDS-CI) in Patients with Myelofibrosis: A Retrospective Study
by: Kira-Lee Koster, et al.
Published: (2023-09-01) -
Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system
by: Vincenzo Accurso, et al.
Published: (2019-03-01) -
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis
by: Francesca Palandri, et al.
Published: (2023-10-01)